CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 352 enrolled
Drug / intervention
GW685698Xdrug
Likely dose
GW685698X 100mcg aqueous nasal spray once dailyAI-extracted
Key inclusion· 3
  • ✓Diagnosis of vasomotor rhinitis (VMR)
  • ✓Outpatient status
  • ✓Literate in English or native language
Key exclusion· 3
  • ✕Significant concomitant medical condition
  • ✕Use of corticosteroids or other allergy medications during the study
  • ✕Tobacco product use within the past year

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00117325
NCT00117325Phase 3Completed
CompareCT.gov

A 4 Week Randomized, Double Blind, Placebo Controlled Study of GW685698X Aq Nasal Spray 100mcg QD in Adults and Adolescents With Vasomotor Rhinitis

GlaxoSmithKline·interventional·Posted Jul 6, 2005·Updated Mar 13, 2018

In Brief

A Phase 3 clinical trial evaluating GW685698X for Rhinitis, Vasomotor. Completed, enrolled 352 participants across 53 sites in 6 countries.

Detailed Summary

The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with vasomotor rhinitis (VMR).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRhinitis, Vasomotor
CountriesCanada, Czechia, Germany, Norway, Romania, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 6, 2005
Enrollment StartJul 11, 2005
Primary CompletionFeb 9, 2006
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 21.0 years ago

Interventions

GW685698Xdrug

Aqueous Nasal Spray 100mcg